Progyny Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Progyny de 22.9% y 15.9% por año respectivamente. Se prevé que el BPA crezca en un 20.7% al año. Se espera que la rentabilidad financiera sea de 20% en 3 años.

Información clave

22.9%

Tasa de crecimiento de los beneficios

20.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	17.2%
Tasa de crecimiento de los ingresos	15.9%
Rentabilidad financiera futura	20.0%
Cobertura de analistas	Good
Última actualización	02 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

May 06

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Jan 25

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Dec 12

Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

Oct 18

Progyny Stock Should Deliver Superior Returns For Investors

Aug 05

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Jul 27

At US$31.63, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Jul 08

Progyny: Solving Infertility Problem

Jul 05

Progyny Stock: A Hidden Gem Tackling Infertility

May 31

Investors Will Want Progyny's (NASDAQ:PGNY) Growth In ROCE To Persist

Apr 18

At US$50.90, Is It Time To Put Progyny, Inc. (NASDAQ:PGNY) On Your Watch List?

Mar 31

Earnings Not Telling The Story For Progyny, Inc. (NASDAQ:PGNY)

Mar 18

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:PGNY - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,872	127	280	286	3
12/31/2025	1,565	105	220	224	9
12/31/2024	1,299	70	172	172	9
12/31/2023	1,089	62	185	189	N/A
9/30/2023	1,033	52	199	203	N/A
6/30/2023	957	49	165	169	N/A
3/31/2023	873	43	109	113	N/A
12/31/2022	787	30	77	80	N/A
9/30/2022	700	42	35	38	N/A
6/30/2022	617	46	38	41	N/A
3/31/2022	551	56	12	14	N/A
12/31/2021	501	66	24	26	N/A
9/30/2021	473	90	22	24	N/A
6/30/2021	450	78	14	15	N/A
3/31/2021	386	58	24	25	N/A
12/31/2020	345	46	35	36	N/A
9/30/2020	310	3	21	24	N/A
6/30/2020	272	-10	11	15	N/A
3/31/2020	264	-5	13	17	N/A
12/31/2019	230	-9	-4	-2	N/A
9/30/2019	194	-6	7	8	N/A
6/30/2019	160	1	1	2	N/A
3/31/2019	130	-4	0	0	N/A
12/31/2018	105	-6	2	2	N/A
12/31/2017	49	-13	-10	-9	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (22.9% al año) de PGNY es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (22.9% al año) de PGNY crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de PGNY crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (15.9% al año) de PGNY crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 15.9% al año) de PGNY crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de PGNY sea baja dentro de 3 años (20%).

Progyny Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024

Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Consensus EPS estimates increase by 28%

Progyny, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Consensus EPS estimates increase by 54%

Progyny, Inc. Raises Financial Guidance for the Full Year Ending December 31, 2023

Recent updates

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Progyny, Inc. to Report Q1, 2024 Results on May 09, 2024

Progyny, Inc., Annual General Meeting, May 23, 2024

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Executive Chairman exercised options and sold US$2.4m worth of stock

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Progyny: Long-Term Thesis Still Intact

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. (NasdaqGS:PGNY) announces an Equity Buyback for $100 million worth of its shares.

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Progyny, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. Announces Executive Appointments

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Executive Chairman exercised options and sold US$5.5m worth of stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Chief Financial Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Progyny, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Consensus EPS estimates increase by 28%

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Progyny, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Executive Chairman exercised options and sold US$4.0m worth of stock

Executive Chairman exercised options and sold US$714k worth of stock

Executive Chairman exercised options and sold US$3.1m worth of stock

Insider recently sold US$54k worth of stock

Consensus EPS estimates increase by 54%

CEO & Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Raises Financial Guidance for the Full Year Ending December 31, 2023

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

CEO & Director exercised options and sold US$318k worth of stock

Consensus EPS estimates fall by 17%

Executive Chairman exercised options and sold US$4.0m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Progyny, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Investor sentiment deteriorates as stock falls 16%

Executive Chairman exercised options and sold US$3.5m worth of stock

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Price target decreased to US$48.57

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Chief Financial Officer recently sold US$543k worth of stock

Independent Director notifies of intention to sell stock

Price target decreased to US$55.57

CEO & Director notifies of intention to sell stock

Consensus EPS estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Progyny, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Executive Chairman exercised options and sold US$87k worth of stock

Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

CEO & Director recently sold US$212k worth of stock

Executive Chairman exercised options and sold US$2.4m worth of stock

Executive Chairman exercised options and sold US$1.6m worth of stock

Progyny, Inc. Appoints Lloyd H. Dean as Class I Director

Consensus EPS estimates increase by 21%

Executive Chairman notifies of intention to sell stock

Progyny, Inc. Provides Earnings Outlook for the Third Quarter and Full Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Progyny Stock Should Deliver Superior Returns For Investors